The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques
Poxvirus vectors represent promising human immunodeficiency virus (HIV) vaccine candidates and were a component of the only successful HIV vaccine efficacy trial to date. We tested the immunogenicity of a novel recombinant capripoxvirus vector, lumpy skin disease virus (LSDV), in combination with modified vaccinia Ankara (MVA), both expressing genes from HIV-1. Here, we demonstrated that the combination regimen was immunogenic in rhesus macaques, inducing high-magnitude, broad and balanced CD4+ and CD8+ T-cell responses, and transient activation of the immune response. These studies support further development of LSDV as a vaccine vector.
AspdenK., PassmoreJ. A., TiedtF., WilliamsonA. L.2003; Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. J Gen Virol 84:1985–1996 [View Article][PubMed]
BurgersW. A., ShephardE., MonroeJ. E., GreenhalghT., BinderA., HurterE., Van HarmelenJ. H., WilliamsonC., WilliamsonA.-L.2008; Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses 24:195–206 [View Article][PubMed]
BurgersW. A., ChegeG. K., MullerT. L., van HarmelenJ. H., KhouryG., ShephardE. G., GrayC. M., WilliamsonC., WilliamsonA. L.2009; Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 90:468–480 [View Article][PubMed]
GarberD. A., O’MaraL. A., GangadharaS., McQuoidM., ZhangX., ZhengR., GillK., VermaM., YuT.other authors2012; Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 86:12605–12615 [View Article][PubMed]
García-ArriazaJ., ArnáezP., GómezC. E., SorzanoC. O., EstebanM.2013; Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PLoS ONE 8:e66894 [View Article][PubMed]
GómezC. E., PerdigueroB., NájeraJ. L., SorzanoC. O., JiménezV., González-SanzR., EstebanM.2012b; Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 86:5026–5038 [View Article][PubMed]
KeeferM. C., FreyS. E., ElizagaM., MetchB., De RosaS. C., BarrosoP. F., TomarasG., CardinaliM., GoepfertP., KalichmanA.2011; A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 29:1948–1958 [View Article][PubMed]
KoffW. C., BurtonD. R., JohnsonP. R., WalkerB. D., KingC. R., NabelG. J., AhmedR., BhanM. K., PlotkinS. A.2013; Accelerating next-generation vaccine development for global disease prevention. Science 340:1232910 [View Article][PubMed]
McElrathM. J., De RosaS. C., MoodieZ., DubeyS., KiersteadL., JanesH., DefaweO. D., CarterD. K., HuralJ.other authors2008; HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis. Lancet 372:1894–1905 [View Article][PubMed]
PerdigueroB., GómezC. E., Di PilatoM., SorzanoC. O., DelaloyeJ., RogerT., CalandraT., PantaleoG., EstebanM.2013; Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS ONE 8:e74831 [View Article][PubMed]
QuinnK. M., Da CostaA., YamamotoA., BerryD., LindsayR. W., DarrahP. A., WangL., ChengC., KongW. P.other authors2013; Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 190:2720–2735 [View Article][PubMed]
Rerks-NgarmS., PitisuttithumP., NitayaphanS., KaewkungwalJ., ChiuJ., ParisR., PremsriN., NamwatC., de SouzaM.other authors2009; Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220 [View Article][PubMed]
ShephardE., BurgersW. A., Van HarmelenJ. H., MonroeJ. E., GreenhalghT., WilliamsonC., WilliamsonA. L.2008; A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res Hum Retroviruses 24:207–217 [View Article][PubMed]
The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques